Kumagai S, Matsunaga I
Department of Occupational Health, Osaka Prefectural Institute of Public Health, Japan.
Occup Environ Med. 1995 Jan;52(1):65-70. doi: 10.1136/oem.52.1.65.
This study aimed to develop a physiologically based pharmacokinetic model for chlorobenzene and to investigate the effect of variation in exposure to chlorobenzene on the chlorobenzene concentration in blood and the urinary concentration of 4-chlorocatechol.
A physiologically based pharmacokinetic model was developed and the simulated results of urinary 4-chlorocatechol concentrations were compared with the values found in experiments and field surveys. The area under the chlorobenzene concentration-time curve in blood (CBBauc) was selected as the measure of internal exposure related to the chronic effect of chlorobenzene. The maximum one-hour time weighted average value of chlorobenzene concentration in blood (CBBmax) was chosen as the measure of internal exposure related to the acute effect of chlorobenzene. The total amount of urinary 4-chlorocatechol (TOTCC) and that excreted during the last four hours (CC(4-8)) or two hours (CC(6-8)) of exposure as well as that excreted during two hours on the next morning (CC(22-24)) were used to represent concentrations of urinary metabolites. The effects of variation of the one-hour time weighted averages of airborne chlorobenzene exposure (CBAs) on the internal exposures and the concentrations of urinary metabolites were investigated with the pharmacokinetic model.
The comparison of the simulated results with the observed data showed that the pharmacokinetic model can be used to estimate the urinary concentrations of 4-chlorocatechol. The CBBauc and TOTCC were not affected by changes in both the geometric SD (GSD) of CBAs or the variations in CBAs. The CBBmax varied with changes in both the GSD and CBAs. The CC(4-8) and CC(6-8) did not vary with the GSD, but these concentrations were affected by the change in the CBAs. Although there was little effect of the GSD and CBAs on the CC(22-24), this value highly reflected the exposure over the preceding days.
To protect workers from the chronic effect of chlorobenzene, it may be sufficient to control the daily average exposure. To protect from the acute effect, however, the short term exposure must be controlled as well. The values of CC(4-8) and CC(6-8) were acceptable for estimating daily average exposure, but the CC(22-24) was not.
本研究旨在建立基于生理学的氯苯药代动力学模型,并研究氯苯暴露变化对血液中氯苯浓度及尿中4-氯邻苯二酚浓度的影响。
建立基于生理学的药代动力学模型,并将尿中4-氯邻苯二酚浓度的模拟结果与实验和现场调查所得值进行比较。选取血液中氯苯浓度-时间曲线下面积(CBBauc)作为与氯苯慢性效应相关的内暴露量度。选取血液中氯苯浓度的最大1小时时间加权平均值(CBBmax)作为与氯苯急性效应相关的内暴露量度。尿中4-氯邻苯二酚总量(TOTCC)、暴露最后4小时(CC(4 - 8))或2小时(CC(6 - 8))排泄的量以及次日上午2小时(CC(22 - 24))排泄的量用于代表尿中代谢物浓度。用药代动力学模型研究空气中氯苯暴露1小时时间加权平均值(CBA)变化对内暴露量及尿中代谢物浓度的影响。
模拟结果与观测数据的比较表明,药代动力学模型可用于估算尿中4-氯邻苯二酚浓度。CBBauc和TOTCC不受CBA几何标准差(GSD)变化或CBA变化的影响。CBBmax随GSD和CBA的变化而变化。CC(4 - 8)和CC(6 - 8)不随GSD变化,但这些浓度受CBA变化的影响。虽然GSD和CBA对CC(22 - 24)影响不大,但该值高度反映了前几天的暴露情况。
为保护工人免受氯苯的慢性影响,控制每日平均暴露量可能就足够了。然而,为防止急性影响,还必须控制短期暴露。CC(4 - 8)和CC(6 - 8)的值可用于估算每日平均暴露量,但CC(22 - 24)的值不可用。